Mediwound, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Okunewitch from Maxim Group maintained a Buy rating on the stock and has a $30.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Okunewitch’s rating is based on several key factors. MediWound’s recent announcement about the commissioning of its expanded manufacturing facility for NexoBrid is a significant development. This expansion is expected to increase the company’s production capacity by six times, which will allow it to meet the current demand that has outpaced supply by a factor of three. The increased capacity positions MediWound to fulfill existing demand and cater to future growth, particularly for NexoBrid, which is an innovative enzymatic burn debridement product.
Additionally, NexoBrid’s approval in major markets such as the US and EU, combined with the estimated $200 million market opportunity in the US alone, underscores its commercial potential. The valuation model considers the commercialization of NexoBrid with a revenue risk adjustment and projects significant revenue growth. These factors, along with the company’s strategic focus on non-surgical, bio-therapeutic solutions for tissue repair, contribute to the Buy rating, with a 12-month price target of $30.